Therapeutic activity of inhibition of the soluble epoxide hydrolase in a mouse model of scrapie

Giorgio Poli, Erica Corda, Piera Anna Martino, Paola Dall'Ara, Silvio R. Bareggi, Giampietro Bondiolotti, Barbara Iulini, Maria Mazza, Cristina Casalone, Sung Hee Hwang, Bruce D. Hammock, Bora Inceoglu

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Aims The misfolding and the aggregation of specific proteins are key features of neurodegenerative diseases, specifically Transmissible Spongiform Encephalopathies (TSEs). In TSEs, neuronal loss and inflammation are associated with the accumulation of the misfolded isoform (PrPsc) of the cellular prion protein (PrPc). Therefore we tested the hypothesis that augmenting a natural anti-inflammatory pathway mediated by epoxygenated fatty acids (EpFAs) will delay lethality. EpFAs are highly potent but enzymatically labile molecules produced by the actions of a number of cytochrome P450 enzymes. Stabilization of these bioactive lipids by inhibiting their degradation mediated by the soluble epoxide hydrolase (sEH) results in potent anti-inflammatory effects in multiple disease models. Main methods Mice were infected with the mouse-adapted RML strain of scrapie by intracerebral or intraperitoneal routes. Animals received the sEH inhibitor, by oral route, administrated in drinking water or vehicle (PEG400). Infected mice were euthanized at a standard clinical end point. Histopathological, immunohistochemical and Western blot analyses of brain tissue confirmed the presence of pathology related to prion infection. Key findings Oral administration of the sEHI did not affect the very short survival time of the intracerebral prion infection group. However, mice infected by intraperitoneal route and treated with t-AUCB survived significantly longer than the control group mice (p < 0.001). Significance These findings support the idea that inhibition of sEH or augmentation of the natural EpFA signaling in the brain offers a potential and different route to understand prion diseases and may become a therapeutic strategy for diseases involving neuroinflammation.

Original languageEnglish (US)
Pages (from-to)1145-1150
Number of pages6
JournalLife Sciences
Volume92
Issue number23
DOIs
StatePublished - Jun 21 2013

Fingerprint

Epoxide Hydrolases
Scrapie
Prions
Fatty Acids
Prion Diseases
Cytochrome P-450 Enzyme System
Brain
Anti-Inflammatory Agents
Neurodegenerative diseases
Pathology
Drinking Water
Protein Isoforms
Animals
Therapeutics
Agglomeration
Stabilization
Tissue
Lipids
Degradation
Infection

Keywords

  • EET
  • Epoxy fatty acid
  • Inflammation
  • Inhibitor
  • Neuroinflammation
  • Prion
  • Soluble epoxide hydrolase

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Poli, G., Corda, E., Martino, P. A., Dall'Ara, P., Bareggi, S. R., Bondiolotti, G., ... Inceoglu, B. (2013). Therapeutic activity of inhibition of the soluble epoxide hydrolase in a mouse model of scrapie. Life Sciences, 92(23), 1145-1150. https://doi.org/10.1016/j.lfs.2013.04.014

Therapeutic activity of inhibition of the soluble epoxide hydrolase in a mouse model of scrapie. / Poli, Giorgio; Corda, Erica; Martino, Piera Anna; Dall'Ara, Paola; Bareggi, Silvio R.; Bondiolotti, Giampietro; Iulini, Barbara; Mazza, Maria; Casalone, Cristina; Hwang, Sung Hee; Hammock, Bruce D.; Inceoglu, Bora.

In: Life Sciences, Vol. 92, No. 23, 21.06.2013, p. 1145-1150.

Research output: Contribution to journalArticle

Poli, G, Corda, E, Martino, PA, Dall'Ara, P, Bareggi, SR, Bondiolotti, G, Iulini, B, Mazza, M, Casalone, C, Hwang, SH, Hammock, BD & Inceoglu, B 2013, 'Therapeutic activity of inhibition of the soluble epoxide hydrolase in a mouse model of scrapie', Life Sciences, vol. 92, no. 23, pp. 1145-1150. https://doi.org/10.1016/j.lfs.2013.04.014
Poli G, Corda E, Martino PA, Dall'Ara P, Bareggi SR, Bondiolotti G et al. Therapeutic activity of inhibition of the soluble epoxide hydrolase in a mouse model of scrapie. Life Sciences. 2013 Jun 21;92(23):1145-1150. https://doi.org/10.1016/j.lfs.2013.04.014
Poli, Giorgio ; Corda, Erica ; Martino, Piera Anna ; Dall'Ara, Paola ; Bareggi, Silvio R. ; Bondiolotti, Giampietro ; Iulini, Barbara ; Mazza, Maria ; Casalone, Cristina ; Hwang, Sung Hee ; Hammock, Bruce D. ; Inceoglu, Bora. / Therapeutic activity of inhibition of the soluble epoxide hydrolase in a mouse model of scrapie. In: Life Sciences. 2013 ; Vol. 92, No. 23. pp. 1145-1150.
@article{238105c2ef7849e493600372c2177268,
title = "Therapeutic activity of inhibition of the soluble epoxide hydrolase in a mouse model of scrapie",
abstract = "Aims The misfolding and the aggregation of specific proteins are key features of neurodegenerative diseases, specifically Transmissible Spongiform Encephalopathies (TSEs). In TSEs, neuronal loss and inflammation are associated with the accumulation of the misfolded isoform (PrPsc) of the cellular prion protein (PrPc). Therefore we tested the hypothesis that augmenting a natural anti-inflammatory pathway mediated by epoxygenated fatty acids (EpFAs) will delay lethality. EpFAs are highly potent but enzymatically labile molecules produced by the actions of a number of cytochrome P450 enzymes. Stabilization of these bioactive lipids by inhibiting their degradation mediated by the soluble epoxide hydrolase (sEH) results in potent anti-inflammatory effects in multiple disease models. Main methods Mice were infected with the mouse-adapted RML strain of scrapie by intracerebral or intraperitoneal routes. Animals received the sEH inhibitor, by oral route, administrated in drinking water or vehicle (PEG400). Infected mice were euthanized at a standard clinical end point. Histopathological, immunohistochemical and Western blot analyses of brain tissue confirmed the presence of pathology related to prion infection. Key findings Oral administration of the sEHI did not affect the very short survival time of the intracerebral prion infection group. However, mice infected by intraperitoneal route and treated with t-AUCB survived significantly longer than the control group mice (p < 0.001). Significance These findings support the idea that inhibition of sEH or augmentation of the natural EpFA signaling in the brain offers a potential and different route to understand prion diseases and may become a therapeutic strategy for diseases involving neuroinflammation.",
keywords = "EET, Epoxy fatty acid, Inflammation, Inhibitor, Neuroinflammation, Prion, Soluble epoxide hydrolase",
author = "Giorgio Poli and Erica Corda and Martino, {Piera Anna} and Paola Dall'Ara and Bareggi, {Silvio R.} and Giampietro Bondiolotti and Barbara Iulini and Maria Mazza and Cristina Casalone and Hwang, {Sung Hee} and Hammock, {Bruce D.} and Bora Inceoglu",
year = "2013",
month = "6",
day = "21",
doi = "10.1016/j.lfs.2013.04.014",
language = "English (US)",
volume = "92",
pages = "1145--1150",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "23",

}

TY - JOUR

T1 - Therapeutic activity of inhibition of the soluble epoxide hydrolase in a mouse model of scrapie

AU - Poli, Giorgio

AU - Corda, Erica

AU - Martino, Piera Anna

AU - Dall'Ara, Paola

AU - Bareggi, Silvio R.

AU - Bondiolotti, Giampietro

AU - Iulini, Barbara

AU - Mazza, Maria

AU - Casalone, Cristina

AU - Hwang, Sung Hee

AU - Hammock, Bruce D.

AU - Inceoglu, Bora

PY - 2013/6/21

Y1 - 2013/6/21

N2 - Aims The misfolding and the aggregation of specific proteins are key features of neurodegenerative diseases, specifically Transmissible Spongiform Encephalopathies (TSEs). In TSEs, neuronal loss and inflammation are associated with the accumulation of the misfolded isoform (PrPsc) of the cellular prion protein (PrPc). Therefore we tested the hypothesis that augmenting a natural anti-inflammatory pathway mediated by epoxygenated fatty acids (EpFAs) will delay lethality. EpFAs are highly potent but enzymatically labile molecules produced by the actions of a number of cytochrome P450 enzymes. Stabilization of these bioactive lipids by inhibiting their degradation mediated by the soluble epoxide hydrolase (sEH) results in potent anti-inflammatory effects in multiple disease models. Main methods Mice were infected with the mouse-adapted RML strain of scrapie by intracerebral or intraperitoneal routes. Animals received the sEH inhibitor, by oral route, administrated in drinking water or vehicle (PEG400). Infected mice were euthanized at a standard clinical end point. Histopathological, immunohistochemical and Western blot analyses of brain tissue confirmed the presence of pathology related to prion infection. Key findings Oral administration of the sEHI did not affect the very short survival time of the intracerebral prion infection group. However, mice infected by intraperitoneal route and treated with t-AUCB survived significantly longer than the control group mice (p < 0.001). Significance These findings support the idea that inhibition of sEH or augmentation of the natural EpFA signaling in the brain offers a potential and different route to understand prion diseases and may become a therapeutic strategy for diseases involving neuroinflammation.

AB - Aims The misfolding and the aggregation of specific proteins are key features of neurodegenerative diseases, specifically Transmissible Spongiform Encephalopathies (TSEs). In TSEs, neuronal loss and inflammation are associated with the accumulation of the misfolded isoform (PrPsc) of the cellular prion protein (PrPc). Therefore we tested the hypothesis that augmenting a natural anti-inflammatory pathway mediated by epoxygenated fatty acids (EpFAs) will delay lethality. EpFAs are highly potent but enzymatically labile molecules produced by the actions of a number of cytochrome P450 enzymes. Stabilization of these bioactive lipids by inhibiting their degradation mediated by the soluble epoxide hydrolase (sEH) results in potent anti-inflammatory effects in multiple disease models. Main methods Mice were infected with the mouse-adapted RML strain of scrapie by intracerebral or intraperitoneal routes. Animals received the sEH inhibitor, by oral route, administrated in drinking water or vehicle (PEG400). Infected mice were euthanized at a standard clinical end point. Histopathological, immunohistochemical and Western blot analyses of brain tissue confirmed the presence of pathology related to prion infection. Key findings Oral administration of the sEHI did not affect the very short survival time of the intracerebral prion infection group. However, mice infected by intraperitoneal route and treated with t-AUCB survived significantly longer than the control group mice (p < 0.001). Significance These findings support the idea that inhibition of sEH or augmentation of the natural EpFA signaling in the brain offers a potential and different route to understand prion diseases and may become a therapeutic strategy for diseases involving neuroinflammation.

KW - EET

KW - Epoxy fatty acid

KW - Inflammation

KW - Inhibitor

KW - Neuroinflammation

KW - Prion

KW - Soluble epoxide hydrolase

UR - http://www.scopus.com/inward/record.url?scp=84878530520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878530520&partnerID=8YFLogxK

U2 - 10.1016/j.lfs.2013.04.014

DO - 10.1016/j.lfs.2013.04.014

M3 - Article

C2 - 23651659

AN - SCOPUS:84878530520

VL - 92

SP - 1145

EP - 1150

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 23

ER -